当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Research progress of azido-containing Pt(IV) antitumor compounds
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2021-10-16 , DOI: 10.1016/j.ejmech.2021.113927
Meilin Mu 1 , Jiuyu Zhan 1 , Xiaohan Dai 1 , Hongwei Gao 1
Affiliation  

Cancer is a long-known incurable disease, and the medical use of cisplatin has been a significant discovery. However, the side-effects of cisplatin necessitate the development of new and improved drug. Therefore, in this study, we focused on the photoactivatable Pt(IV) compounds Pt[(X1)(X2)(Y1)(Y2)(N3)2], which have a completely novel mechanism of action. Pt(IV) can efficiently overcome the side-effects of cisplatin and other drugs. Here, we have demonstrated, summarized and discussed the effects and mechanism of these compounds. Compared to the relevant articles in the literature, we have provided a more detailed introduction and a made comprehensive classification of these compounds. We believe that our results can effectively provide a reference for the development of these drugs.



中文翻译:

含叠氮基Pt(IV)抗肿瘤化合物的研究进展

癌症是一种久负盛名的不治之症,顺铂的医学用途是一项重大发现。然而,顺铂的副作用需要开发新的和改进的药物。因此,在这项研究中,我们专注于可光活化的 Pt(IV) 化合物 Pt[(X 1 )(X 2 )(Y 1 )(Y 2 )(N 3 ) 2],具有全新的作用机制。Pt(IV)能有效克服顺铂等药物的副作用。在这里,我们展示、总结和讨论了这些化合物的作用和机制。与文献中的相关文章相比,我们对这些化合物进行了更详细的介绍和全面的分类。我们相信我们的研究结果可以有效地为这些药物的开发提供参考。

更新日期:2021-10-22
down
wechat
bug